Zhonglian F. Cao

12 Wulumuqi Middle Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Targeting ANGPTL3 and IL-33/ST2 Ameliorates Diabetic Kidney Disease by Reducing Lipotoxicity, Alleviating Inflammation and Inhibiting Fibrosis.

Targeting ANGPTL3 and IL-33/ST2 Ameliorates Diabetic Kidney Disease by Reducing Lipotoxicity, Alleviating Inflammation and Inhibiting Fibrosis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 12, 2026

Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db mice.

Targeting angiopoietin-like protein 3 and interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and regulation of glycolipid metabolism in db/db mice.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: October 23, 2025

G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.

G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.

Journal: Circulation

Published: August 07, 2025

ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress.

ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress.

Journal: International journal of biological macromolecules

Published: June 18, 2025

Correction to "PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation".

Correction to "PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation".

Journal: Journal of medicinal chemistry

Published: June 13, 2025

PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation.

PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation.

Journal: Journal of medicinal chemistry

Published: April 14, 2025

Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen.

Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen.

Journal: Journal of medicinal chemistry

Published: September 13, 2024

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: August 14, 2024

Research progress of m6A methylation modification in renal cell carcinoma

Research progress of m6A methylation modification in renal cell carcinoma

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: August 05, 2024

Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation.

Simultaneously blocking ANGPTL3 and CD47 prevents the progression of atherosclerosis through regulating lipid metabolism, macrophagic efferocytosis and lipid peroxidation.

Journal: Pharmacological research

Published: August 04, 2024

Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota.

Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota.

Journal: Phytotherapy research : PTR

Published: June 05, 2024

Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy.

Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy.

Journal: European journal of medicinal chemistry

Published: May 05, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026